The Future of RNA Therapeutics
AVI BioPharma is focused on the discovery and development of RNA–based drugs utilizing an extensive proprietary technology platform with applications to a range of diseases and genetic disorders.
AVI’s RNA–based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy and for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Medical Company. Our antiviral programs have demonstrated promising effects in Ebola Zaire and Marburg Musoke viruses and may prove applicable to other viral targets such as HCV and Dengue viruses.
AVI BioPharma — Advancing RNA Drug Development and Discovery to Improve Human Medicines